ABSTRACT
Introduction
Sitagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. DPP-4 inhibitors are remarkably well tolerated oral antihyperglycemic drugs with an adverse effect profile similar to that of placebo [1] . The other advantages with this class include that they are weight neutral and hypoglycemia is rare [1] . Although the currently available DPP-4 inhibitors are thought to be highly selective, continued long-term surveillance for unexpected adverse events is essential. The multiplicity of substrates and peptide fragments whose biology DPP-4 inhibitors affect imparts complexity to the biology of these agents [2] .
We present here case summary of a 35-year-old female with type 2 diabetes mellitus (T2DM) and major depressive disorder who presented with multiple splenic infarcts after ingestion of sitagliptin 700 mg and metformin 14 g with suicidal intent (7 times greater than the approved maximum daily dose of sitagliptin and over 5 times the approved maximum daily dose of metformin). To the best of our knowledge, there are no published reports of splenic infarcts as an adverse event of sitagliptin.
Case study
A 35-year-old normotensive female, known to have T2DM for last 11 years and major depressive disorder presented with severe left upper quadrant pain accompanied by pleuritic chest pain and left shoulder pain of few days duration. The pain was associated with nausea and vomiting. She was conscious and alert. Her blood pressure was 140/80 mm Hg. Abdominal examination revealed left upper quadrant tenderness. Her medications included 2 doses of premixed insulin, a fixed -dose combination pill of sitagliptin 50 mg and metformin 1000 mg, levothyroxine 50 mg and escitalopram 20 mg. She had been on sitagliptin for last 2 years and on insulin for last 8 months. She had poor glycemic control as reflected by HbA 1c of 8.5% and fasting plasma glucose of 200 mg/dL and postprandial glucose of 320 mg/dL. Baseline investigations including complete blood counts, hematocrit, ESR, kidney and liver function tests were unremarkable; total platelet count was 2.2 lacs/mm 3 . Serum amylase was normal. Ultrasonography abdomen was normal. Pain was managed with analgesics and she was advised to report back in case of persistence/worsening of symptoms. Patient reported back two days later with worsening of pain. On further revision of history, she admitted that she had taken 14 fixed-dose combination pills containing sitagliptin 50 mg + metformin 1000 mg each, amounting to a total ingestion of sitagliptin 700 mg and metformin 14 g with suicidal intent one day prior to the development of symptoms.
For further evaluation of her symptoms, contrast enhanced computed tomography (CECT) of the abdomen was performed which revealed multiple fairly well defined hypodense lesions in spleen without any significant enhancement suggestive of splenic infarcts with bilateral minimal basal atelectasis (Fig. 1A and B) . CECT also revealed minimal fluid and fat strandings posteroinferior to spleen. Serum pH was normal as was serum lactate levels. A detailed clinical and investigative work up was undertaken to find any possible etiology of splenic infarcts. There was no clinical suggestion of the presence of underlying hematological, thromboembolic or collagen vascular disease. The patient had never taken estrogens. Echocardiography did not reveal any evidence of valvular lesion or endocarditis. The D-dimer test and antinuclear antibody were negative. Coagulogram was normal. Serum protein C, protein S, homocysteine levels were normal. The serology for hepatitis C was negative. The work up for anti-phospholipid antibody syndrome (lupus anticoagulant, antiphospholipid antibodies IgG and IgM, dilute Russell Viper Venom test) was negative.
A clear temporal relation between ingestion of "large doses" of sitagliptin and development of splenic infarcts together with negative results in the work up for any known etiologies of splenic infarct strongly incriminate sitagliptin as the cause for splenic infarcts in our patient. Patient was taken off sitagliptin and the other medications were continued. Her management included hydration, analgesics, and frequent monitoring. After few days her symptoms abated and she was completely asymptomatic a week later. A repeat CECT abdomen could not be undertaken as the patient declined it.
Discussion
The adverse effect profile DPP-4 inhibitors is similar to that of placebo and no adverse effects have been reported even with overdose of DPP-4 inhibitors [3, 4] . Furukawa et al., reported no adverse effects in a 86-year-old woman with type 2 diabetes and depression, after ingestion of 1,700 mg of sitagliptin (17 times greater than the approved maximum daily dose) with suicidal intent [3] . In another reported case, an overdose of sitagliptin 3500 mg (35 times greater than the approved maximum daily dose) did not lead to any adverse events [4] . This is the highest reported case for sitagliptin overdose. These two published reports reflect that "large doses" of sitagliptin do not lead to any adverse events. Our patient developed splenic infarcts with 700 mg of sitagliptin; this may reflect individual vulnerability to an adverse event with this drug.
An eHealthMe based on reports of 41.491 persons who had side effects with sitagliptin, updated on 25 th Jul, 2017 from FDA, reported splenic infarction in 13 persons (0.03%) [5] . Splenic infarction was reported especially in males, those who had been taking the drug for 2 to 5 years, with concomitant use of exenatide and having essential hypertension. In this report all patients were 60 years of age or older [5] .
The mechanism of sitagliptin induced splenic infarcts is unknown. Thrombosis may be induced with inhibition of DPP-4 activity. DPP-4, also known as CD26, is expressed by microvascular endothelial cells in humans (i.e. in liver, spleen, lungs and brain) and in the hearts of rats [6, 7] . DPP-4 has the potential to inhibit fibrin polymerization and clot formation [8, 9] . Thus DPP-4 may behave as an immobilized anti-coagulant on microvascular endothelium and possesses antithrombotic properties; decreased DPP-4 expression and activity has been found to coincide with an increase in Tissue Factor expression and induction of in situ thrombosis [10] . Inhibition of DPP-4 activity also induces adhesion of platelets; this may be another mechanism of thrombosis which occurs with inhibition of DPP-4 activity [10] . For two reasons we strongly believe that metformin was not responsible for splenic infarcts in our patient. Firstly, metformin has never been reported to cause splenic infarction or infarction of any other viscera. Secondly, metformin has not been reported to have any unfavourable effect on fibrin polymerization, coagulation and platelets.
Our patient was a young female, had been on sitagliptin for 2 years only, was normotensive and had never been on exenatide. To the best of our knowledge this is the first published case report of sitagliptin induced splenic infarcts. Our case highlights that abdominal pain in a patient on sitagliptin may indicate the presence of splenic infarcts and deserves thorough evaluation and management. In addition our case emphasizes that splenic infarcts due to sitagliptin phosphate may occur in young individuals without other risk factors like essential hypertension and the concomitant use of exenatide.
